CLINICAL TRIAL SUMMARY

MDACC Study No:2008-0075 (clinicaltrials.gov NCT No: NCT00603668)
Title:A Phase I/II Study of Immunotherapy with Milatuzumab (hLL1) in Patients with Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Principal Investigator:Felipe Samaniego
Treatment Agent:Milatuzumab
Study Status:Closed
Study Description:The goal of the Phase I part of this clinical research study is to find the
highest tolerable dose of milatuzumab that can be given to patients with NHL or
CLL.

The goal of the Phase II part of this clinical research study is to learn if
milatuzumab can help to control NHL or CLL. The safety of the study drug will
also be studied.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase I/Phase II
Treatment Agents:Milatuzumab
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:None
Supported By:Immunomedics, Inc
Return Visit:Patient will need to come to MDACC weekly for 4 consecutive weeks; then 4 and
12 weeks later.
Follow-up will be every 3 months as need for 2 years.
Home Care:None


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Felipe Samaniego
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults